ESTIMATED ANNUALIZED B	SURDEN HOURS
------------------------	--------------

Respondents	Activity	Number of respondents	Number of responses per respondent	Average burden per response (in hours)
Mothers (interview)	Telephone consent and BD-STEPS questionnaire.	1,925	1	45/60
Mothers (consent for bloodspot retrieval)	Written consent for bloodspot retrieval	1,375	1	15/60
Mothers (online occupational questionnaire)	Online Occupational Questionnaire	642	1	20/60
Mothers (consent for medical records review)	Written release for medical records review	385	1	15/60
Records reviewers (medical records review)	Pulling and sending records	385	1	30/60

#### Leroy A. Richardson,

Chief, Information Collection Review Office, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention.

[FR Doc. 2015-13385 Filed 6-1-15; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Centers for Disease Control and Prevention

### Advisory Committee on Immunization Practices

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announce the following federal advisory committee meeting.

Times and dates:

8:00 a.m.-5:15 p.m., June 24, 2015 8:30 a.m.-3:30 p.m. June 25, 2015

8:30 a.m.–3:30 p.m., June 25, 2015 Place: CDC, Tom Harkin Global Communications Center, 1600 Clifton Road NE., Building 19, Kent "Oz" Nelson Auditorium, Atlanta, Georgia 30333

Status: Open to the public, limited only by the space available. Time will be available for public comment. The public is welcome to submit written comments in advance of the meeting. Comments should be submitted in writing by email to the contact person listed below. The deadline for receipt is June 22, 2015. All requests must contain the name, address, and organizational affiliation of the speaker, as well as the topic being addressed. Written comments should not exceed one singlespaced typed page in length and delivered in three minutes or less. Please note that the public comment period may end before the time indicated, following the last call for comments. Members of the public who wish to provide public comments should plan to attend the public comment session at the start time listed. Written comments received in advance

of the meeting will be included in the official record of the meeting.

The meeting will be webcast live via the World Wide Web; for instructions and more information on ACIP please visit the ACIP Web site: http:// www.cdc.gov/vaccines/acip/index.html

*Purpose:* The committee is charged with advising the Director, CDC, on the appropriate use of immunizing agents. In addition, under 42 U.S.C. 1396s, the committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding the appropriate periodicity, dosage, and contraindications applicable to the vaccines. Further, under provisions of the Affordable Care Act, at section 2713 of the Public Health Service Act, immunization recommendations of the ACIP that have been adopted by the Director of the Centers for Disease Control and Prevention must be covered by applicable health plans.

Matters for discussion: The agenda will include discussions on: Meningococcal vaccines; general recommendations; human papillomavirus vaccines; influenza; influenza A(H5N1) vaccine, tetanus, diphtheria, and acellular pertussis (Tdap) vaccine; combination vaccines; smallpox vaccine in laboratory personnel; pneumococcal vaccines; child/adolescent immunization schedule; herpes zoster vaccines; Japanese encephalitis vaccine and vaccine supply. Recommendation votes are scheduled for meningococcal vaccines, influenza, influenza A (H5N1), smallpox vaccine in laboratory personnel, general recommendations and pneumococcal vaccines. A Vaccines for Children (VCF) vote is scheduled for meningococcal vaccines.

Agenda items are subject to change as priorities dictate.

Contact person for more information: Stephanie Thomas, National Center for Immunization and Respiratory Diseases, CDC, 1600 Clifton Road NE., MS–A27, Atlanta, Georgia 30333, telephone 404/639–8836; Email *ACIP@CDC.GOV* 

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

#### Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2015–13312 Filed 6–1–15; 8:45 am]

BILLING CODE 4160-18-P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Centers for Disease Control and Prevention

### Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces a meeting for the initial review of applications in response to PA 07–318, NIOSH Member Conflict Review.

Time and date: 1:00 p.m.–4:00 p.m., EST, June 25, 2015 (Closed)

Place: Teleconference.

Status: The meeting will be closed to the public in accordance with provisions set forth in section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

Matters for discussion: The meeting will include the initial review, discussion, and evaluation of applications received in response to "NIOSH Member Conflict PA 07–318."

Contact person for more information: Nina Turner, Ph.D., Scientific Review